Canaccord analyst Richard Close lowered the firm’s price target on Evolent Health (EVH) to $4 from $9 and keeps a Buy rating on the shares. The firm said Evolent has continued to suffer this year, trading down roughly 36% as fears of continued medical cost pressures on managed care and the impact of ACA exchange membership has concerned investors. It appears that under the fingerprints of the new CFO Mario Ramos, Evolent is increasing transparency and the level of conservatism baked into its guidance,
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating
- Evolent Health downgraded to Sector Weight from Overweight at KeyBanc
- Evolent Health reports Q4 adjusted EPS 8c vs. (2c) last year
- Evolent Health sees FY26 revenue $2.4B-$2.6B, consensus $2.38B
- EVH Upcoming Earnings Report: What to Expect?